Johnson & Johnson announced that Jennifer Taubert will retire as Executive Vice President and Worldwide Chairman, Innovative Medicine. Tom Cavanaugh, currently Company Group Chairman for North America, Innovative Medicine, will succeed her and join…
BioNTech’s Supervisory Board has appointed Guido Oelkers to the Management Board as Chief Executive Officer, effective no later than February 1, 2027. He succeeds co-founder Ugur Sahin, who will support the onboarding transition and…
Tempus AI agreed to acquire Personalis for $16.25 per share, representing an enterprise value of approximately $1.5 billion net of Tempus’ existing ownership. The deal integrates Personalis’ tumor-informed minimal residual disease testing with Tempus’…
Bristol Myers Squibb is expanding its NVIDIA collaboration with a second DGX SuperPOD built on eight Vera Rubin NVL72 systems. The infrastructure is intended to make large-scale AI broadly available across BMS research, from…
Ipsen will acquire Memo Therapeutics for up to EUR700M including EUR200M upfront, adding potravitug, a Phase 2 monoclonal antibody for BK polyomavirus-associated nephropathy in kidney transplant recipients.
Parabilis, formerly FogPharma, increased its planned IPO size to as much as $636.8 million, potentially becoming one of the largest biotech IPOs in recent years. The financing represents a major validation event for the…
Pfizer has discontinued a Phase 1 immunostimulatory drug-conjugate program in oncology, highlighting challenges in developing next-generation targeted delivery modalities.
